FY2025 · ended Dec 31, 2025 · Revenue $35.95M, +1.0% YoY · Filed Feb 26, 2026
C4 Therapeutics, Inc. (CCCC) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $35.9 million and a net loss of $105.0 million. Free cash flow was -$99.3 million. As of Sep 30, 2026 it held $32.4 million in cash and investments and $55.2 million in total debt.
Revenue (TTM)
$32.28M
Net income (TTM)
$-91.09M
Operating cash flow (TTM)
$-79.63M
Free cash flow (TTM)
$-79.74M
EPS (TTM)
$-0.72
Dividend per share
None
Shares outstanding
97.58M
+37.5% vs prior year
Net cash
$-22.82M
as of Sep 30, 2026
Operating margin
-315.9%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CCCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662579
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | — |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M | -$83.9M |
| Diluted EPS | -$1.27 | -$1.52 | -$2.67 | -$2.62 | — |
| Operating cash flow | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M |
| Stockholders' equity | $256.6M | $216.0M | $246.1M | $289.2M | $389.6M |
| Cash and investments | $74.6M | $55.5M | $126.6M | $29.8M | $451.5M |
| Total debt | $60.0M | $65.8M | $71.0M | $87.2M | $42.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 25, 2026 | Sep 25, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
May 15, 2026 | May 15, 2026 |
All 546 C4 Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.